EMA validates R/F/TAF MAA for the treatment of HIV-1
21 August 2015 | By Victoria White
An MAA for an investigational regimen that combines emtricitabine, tenofovir alafenamide and rilpivirine (R/F/TAF) has been fully validated by the EMA...
List view / Grid view
News
Coulter Partners appoints PR and Marketing Manager
21 August 2015 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointment of Alison James as PR and Marketing Manager...
Dolomite Flow Chemistry Systems launched at 250th ACS Exposition
21 August 2015 | By Dolomite
Dolomite, a world leader in microfluidics innovation, has launched new flexible, cost-effective Flow Chemistry Systems at the 250th American Chemical Society Meeting and Exposition in August 2015...
EMA validates MAA for Pfizer’s Ibrance
21 August 2015 | By Victoria White
The EMA has validated for review a MAA for Ibrance in combination with endocrine therapy for the treatment of HR+/HER2- metastatic breast cancer...
EMA accepts MAA for multiple myeloma drug ixazomib
21 August 2015 | By Victoria White
Takeda has announced that the EMA has accepted is Marketing Authorisation Application for ixazomib for the treatment of patients with multiple myeloma...
EC approves Odomzo for basal cell carcinoma
20 August 2015 | By Victoria White
The EC has approved Novartis’ Odomzo (sonidegib) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma...
Multiple myeloma treatment market value to approach $9 billion by 2021
20 August 2015 | By Victoria White
The global multiple myeloma treatment market value will expand from $7.3 billion in 2014 to $8.9 billion by 2021, says GBI Research...
Valeant to acquire Sprout for $1 billion
20 August 2015 | By Victoria White
Valeant has entered into a definitive agreement to acquire Sprout, makers of female libido drug Addyi, for approximately $1 billion...
Jardiance demonstrates CV risk reduction in type 2 diabetes
20 August 2015 | By Victoria White
Boehringer Ingelheim and Lilly have announced positive top-line results from a clinical study investigating cardiovascular (CV) outcomes for Jardiance...
Vernalis completes investment in NCE development pipeline
20 August 2015 | By Victoria White
Vernalis has announced results from a Phase II proof-of-concept study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor...
Pharma companies rank high on Forbes’ most innovative list
19 August 2015 | By Victoria White
Alexion, Regeneron,Incyte and BioMarin have all been ranked in the top ten on Forbes magazine's 2015 list of the "World's Most Innovative Companies"...
NIAID provides more funding to advance ricin vaccine RiVax
19 August 2015 | By Victoria White
NIAID has provided Soligenix an additional $2.7 million in funding to advance the development of its heat stabilised ricin toxin vaccine, RiVax...
Kuros closes successful CHF 15m financing round
19 August 2015 | By Victoria White
Kuros, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products, has closed a financing round of CHF15M...
FDA approves female libido drug Addyi
19 August 2015 | By
The US FDA has approved Sprout’s Addyi (flibanserin) to treat acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women...
Bavarian Nordic initiates Phase 1 clinical trial of MVA-BN RSV vaccine
18 August 2015 | By Victoria White
Bavarian Nordic has initiated a Phase 1 clinical study of its MVA-BN vaccine candidate against respiratory syncytial virus (RSV)...
